Viaggi per imprenditori nel mercato target Viaggi per imprenditori legati a un tema o a un settore e personalizzati per ampliare la vostra rete nel mercato target.
Business travel in the target market Individualized and group business trips on specific topics or industries to expand your network in the target market.
Voyages de prospection sur le marché cible Voyages de prospection thématiques ou sectoriels, en groupe ou individuels, pour élargir votre réseau sur le marché cible.
Tool UNDP UNDP provides enterprises, business incubators and external accelerators with advisory, expertise and tools to enable implementation and accelera...
Tool UNDP UNDP provides enterprises, business incubators and external accelerators with advisory, expertise and tools to enable implementation and accelera...
News 11. Apr. 2024 Circunis obtains funding from the Seedling Foundation Circunis has secured financing to establish an online marketplace that can be used to trade surplus food and by-products. Following in the footst...
Unternehmerreisen im Zielmarkt Themen- oder branchenspezifischen und individualisierte Unternehmerreisen zur Erweiterung Ihres Netzwerks im Zielmarkt.
News 09. Apr. 2024 DESI project unveils groundbreaking 3D universe map with EPFL’s aid EPFL astrophysicists have contributed to creating the most detailed 3D map of the universe, tracing expansion over 11 billion years.
Viaggi per imprenditori Viaggio di prospezione in Armenia: Business Forum 2024 BERS & SWISS Days 13. Mai 2024–16. Mai 2024 Armenien
Unternehmerreisen Swiss Days Armenia and Swiss Business Delegation to EBRD Business Forum 13. Mai 2024–16. Mai 2024 Armenien
Actualités 17. Apr. 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 10. Okt. 2023 HES-SO Valais-Wallis and Debiopharm partner up to battle cancer HES-SO Valais-Wallis and Debiopharm have entered a partnership to advance targeted cancer therapy research with novel antibody conjugates.
